Raymond Dwek Biography and Net Worth
Prof. Raymond A. Dwek CBE serves as Independent Director
of the Company. Professor Dwek is a Fellow of the Royal Society, London, and has served as Director of the Glycobiology Institute at the University of Oxford since 1988. He also served as Professor of Glycobiology at the University of Oxford from 1988 through 2009, and currently serves as Professor Emeritus. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and Nasdaq, and he served as a member of its Board of Directors until its sale in 2003. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis and biology of sugar chains attached to proteins. He has served as a United Therapeutics director since 2002.
What is Raymond A. Dwek's net worth?
The estimated net worth of Raymond A. Dwek is at least $963,148.00 as of June 29th, 2020. Mr. Dwek owns 4,600 shares of United Therapeutics stock worth more than $963,148 as of October 1st. This net worth approximation does not reflect any other assets that Mr. Dwek may own. Learn More about Raymond A. Dwek's net worth.
How do I contact Raymond A. Dwek?
Has Raymond A. Dwek been buying or selling shares of United Therapeutics?
Raymond A. Dwek has not been actively trading shares of United Therapeutics during the past quarter. Most recently, Raymond Dwek sold 2,160 shares of the business's stock in a transaction on Monday, July 11th. The shares were sold at an average price of $241.29, for a transaction totalling $521,186.40. Learn More on Raymond A. Dwek's trading history.
Who are United Therapeutics' active insiders?
Are insiders buying or selling shares of United Therapeutics?
During the last twelve months, insiders at the biotechnology company sold shares 40 times. They sold a total of 180,188 shares worth more than $36,790,592.05. The most recent insider tranaction occured on September, 28th when Director Nilda Mesa sold 850 shares worth more than $179,392.50. Insiders at United Therapeutics own 12.4 % of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 9/28/2022.
Raymond A. Dwek Insider Trading History at United Therapeutics
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
United Therapeutics Company Overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
50 Day Range
2 Week Range